Fed. Circ. Allows AbbVie, J&J To Fend Off Imbruvica Generic
The Federal Circuit on Tuesday handed a win to Abbvie's Pharmacyclics and Johnson & Johnson's Janssen Biotech by saying a generic version of their blockbuster cancer drug Imbruvica infringes their patents,...To view the full article, register now.
Already a subscriber? Click here to view full article